Thoraxklinik Heidelberg gGmbH
- Address
- lock Available on a paid plan
Thoraxonkologie Heidelberg - Neoplasms
Clinical research at Thoraxklinik Heidelberg gGmbH is strongly focused on cancer, especially lung cancer and related thoracic tumors. Studies are examining whether newer treatment combinations can improve survival, slow disease progression, and offer better options for patients with advanced or previously treated disease.
- Small cell lung cancer and extensive-stage small-cell lung cancer
- Non-Small Cell Lung Cancer (NSCLC), including metastatic and c-Met overexpressing forms
- Pleural mesothelioma, neuroendocrine carcinoma, and other aggressive thoracic cancers
These trials are mainly testing new therapies and comparing them with current standards of care to find more effective approaches for hard-to-treat thoracic malignancies.
Respiratory Tract Diseases
The site also supports important studies in respiratory disease, with a particular emphasis on chronic and progressive lung conditions. Research here is aimed at improving breathing capacity, preserving lung function, and easing the long-term impact of serious pulmonary illness.
- Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
- Pulmonary arterial hypertension and related forms of PAH
- Trials assessing symptom control, exercise tolerance, and disease progression
At this Heidelberg hospital, the goal is to evaluate new treatments that may better manage debilitating lung diseases and improve day-to-day function for patients.
Cardiovascular Diseases and Pulmonary Vascular Research
Another key area of research involves pulmonary vascular disease, bridging cardiovascular and respiratory medicine. The studies are centered on pulmonary arterial hypertension, where investigators are looking for therapies that can reduce disease burden and improve physical capacity.
- Pulmonary arterial hypertension in multiple patient groups
- Measures of exercise ability and vascular resistance
- Evaluation of treatment effectiveness in a chronic, high-impact condition
These trials reflect a broader effort to advance care for patients with serious cardiopulmonary disorders through better disease control and functional outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 153 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 150 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 32 by active trials.
- 1AstraZeneca AB7active
lock +31 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB11trials
lock +24 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Thoraxklinik Heidelberg gGmbH
lock Showing 1 of 133 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW) | Rein Therapeutics Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 153 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 31 | Unknown | 2018-08-09 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
